請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9821
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
dc.contributor.author | Ya-Hui Wang | en |
dc.contributor.author | 王雅蕙 | zh_TW |
dc.date.accessioned | 2021-05-20T20:43:24Z | - |
dc.date.available | 2013-09-11 | |
dc.date.available | 2021-05-20T20:43:24Z | - |
dc.date.copyright | 2008-09-11 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-20 | |
dc.identifier.citation | 1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119:1946-52. 3. Taiwan BoHPDoHtEY. Cancer registry annual report, 2005 Taiwan. In. Taiwan; 2007. 4. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991;51:5621-5. 5. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004;127:S72-8. 6. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943-6. 7. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17:71-91. 8. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159-64. 9. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995;109:1266-73. 10. Hsieh LL, Huang RC, Yu MW, Chen CJ, Liaw YF. L-myc, GST M1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers. Cancer Lett 1996;103:171-6. 11. Chen CJ, Yu MW, Liaw YF, Wang LW, Chiamprasert S, Matin F, et al. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet 1996;59:128-34. 12. Yu MW, Chiu YH, Yang SY, Santella RM, Chern HD, Liaw YF, et al. Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Br J Cancer 1999;80:598-603. 13. Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2000;92:2023-8. 14. Chen CC, Yang SY, Liu CJ, Lin CL, Liaw YF, Lin SM, et al. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol 2005;34:1310-8. 15. Yu MW, Yang SY, Pan IJ, Lin CL, Liu CJ, Liaw YF, et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2003;95:1485-8. 16. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999;29:697-702. 17. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008;299:53-60. 18. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005;6:95-108. 19. Sheu JC, Lin YW, Chou HC, Huang GT, Lee HS, Lin YH, et al. Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan. Br J Cancer 1999;80:468-76. 20. Midorikawa Y, Yamamoto S, Ishikawa S, Kamimura N, Igarashi H, Sugimura H, et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene 2006;25:5581-90. 21. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73. 22. Lu T, Hano H, Meng C, Nagatsuma K, Chiba S, Ikegami M. Frequent loss of heterozygosity in two distinct regions, 8p23.1 and 8p22, in hepatocellular carcinoma. World J Gastroenterol 2007;13:1090-7. 23. Sun M, Eshleman JR, Ferrell LD, Jacobs G, Sudilovsky EC, Tuthill R, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001;33:1415-24. 24. Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC, Chen DS. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res 1994;54:4188-92. 25. Weith A, Martinsson T, Cziepluch C, Bruderlein S, Amler LC, Berthold F, et al. Neuroblastoma consensus deletion maps to 1p36.1-2. Genes Chromosomes Cancer 1989;1:159-66. 26. Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000;18:3604-13. 27. Chuang CF. Linkage mapping hepatocellular-carcinoma susceptibility loci on chromosome 1p (Master thesis); 2006. 28. Zhu M, Zhao S. Candidate gene identification approach: progress and challenges. Int J Biol Sci 2007;3:420-7. 29. Ali M, Kim H, Cleary S, Cupples C, Gallinger S, Bristow R. Characterization of Mutant MUTYH Proteins Associated With Familial Colorectal Cancer. Gastroenterology 2008. 30. Spinola M, Falvella FS, Galvan A, Pignatiello C, Leoni VP, Pastorino U, et al. Ethnic differences in frequencies of gene polymorphisms in the MYCL1 region and modulation of lung cancer patients' survival. Lung Cancer 2007;55:271-7. 31. Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001;93:1644-51. 32. Hamosh A, Scott AF, Amberger J, Valle D, McKusick VA. Online Mendelian Inheritance in Man (OMIM). Hum Mutat 2000;15:57-61. 33. Su WH, Chao CC, Yeh SH, Chen DS, Chen PJ, Jou YS. OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res 2007;35:D727-31. 34. Conde L, Vaquerizas JM, Dopazo H, Arbiza L, Reumers J, Rousseau F, et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res 2006;34:W621-5. 35. Grover D, Woodfield AS, Verma R, Zandi PP, Levinson DF, Potash JB. QuickSNP: an automated web server for selection of tagSNPs. Nucleic Acids Res 2007;35:W115-20. 36. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res 2005;15:1592-3. 37. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998;63:259-66. 38. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003;25:115-21. 39. Laird NM, Horvath S, Xu X. Implementing a unified approach to family-based tests of association. Genet Epidemiol 2000;19:S36-42. 40. Horvath S, Xu X, Lake SL, Silverman EK, Weiss ST, Laird NM. Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol 2004;26:61-9. 41. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5. 42. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36. 43. Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics 2005;21:2128-9. 44. Li M, Boehnke M, Abecasis GR. Joint modeling of linkage and association: identifying SNPs responsible for a linkage signal. Am J Hum Genet 2005;76:934-49. 45. Goring HH, Terwilliger JD. Linkage analysis in the presence of errors IV: joint pseudomarker analysis of linkage and/or linkage disequilibrium on a mixture of pedigrees and singletons when the mode of inheritance cannot be accurately specified. Am J Hum Genet 2000;66:1310-27. 46. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002;30:3894-900. 47. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001;11:863-74. 48. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C, Ramasamy K, et al. Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med 2005;352:884-94. 49. Douglas JA, Zuhlke KA, Beebe-Dimmer J, Levin AM, Gruber SB, Wood DP, et al. Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev 2005;14:2035-9. 50. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39:168-77. 51. Scuto A, Zhang H, Zhao H, Rivera M, Yeatman TJ, Jove R, et al. RbAp48 regulates cytoskeletal organization and morphology by increasing K-Ras activity and signaling through mitogen-activated protein kinase. Cancer Res 2007;67:10317-24. 52. Qian YW, Wang YC, Hollingsworth RE, Jr., Jones D, Ling N, Lee EY. A retinoblastoma-binding protein related to a negative regulator of Ras in yeast. Nature 1993;364:648-52. 53. Henikoff S. Versatile assembler. Nature 2003;423:814-5, 817. 54. Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002;111:197-208. 55. Kong L, Yu XP, Bai XH, Zhang WF, Zhang Y, Zhao WM, et al. RbAp48 is a critical mediator controlling the transforming activity of human papillomavirus type 16 in cervical cancer. J Biol Chem 2007;282:26381-91. 56. Chang H, Fujita T. PicSNP: a browsable catalog of nonsynonymous single nucleotide polymorphisms in the human genome. Biochem Biophys Res Commun 2001;287:288-91. 57. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005;310:317-20. 58. Werner SR, Lee PA, DeCamp MW, Crowell DN, Randall SK, Crowell PL. Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases. Cancer Lett 2003;202:201-11. 59. Dumaual CM, Sandusky GE, Crowell PL, Randall SK. Cellular localization of PRL-1 and PRL-2 gene expression in normal adult human tissues. J Histochem Cytochem 2006;54:1401-12. 60. Wang Y, Li ZF, He J, Li YL, Zhu GB, Zhang LH. Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis. Int J Colorectal Dis 2007;22:1179-84. 61. Barlat I, Maurier F, Duchesne M, Guitard E, Tocque B, Schweighoffer F. A role for Sam68 in cell cycle progression antagonized by a spliced variant within the KH domain. J Biol Chem 1997;272:3129-32. 62. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 2008;13:343-54. 63. Lazer G, Pe'er L, Schapira V, Richard S, Katzav S. The association of Sam68 with Vav1 contributes to tumorigenesis. Cell Signal 2007;19:2479-86. 64. Ahlemann M, Zeidler R, Lang S, Mack B, Munz M, Gires O. Carcinoma-associated eIF3i overexpression facilitates mTOR-dependent growth transformation. Mol Carcinog 2006;45:957-67. 65. Song H, Xia SL, Liao C, Li YL, Wang YF, Li TP, et al. Genes encoding Pir51, Beclin 1, RbAp48 and aldolase b are up or down-regulated in human primary hepatocellular carcinoma. World J Gastroenterol 2004;10:509-13. 66. Pacifico F, Paolillo M, Chiappetta G, Crescenzi E, Arena S, Scaloni A, et al. RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer. J Clin Endocrinol Metab 2007;92:1458-66. 67. Teufel A, Malik N, Mukhopadhyay M, Westphal H. Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. Gene 2002;297:79-83. 68. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004;431:873-8. 69. Wolfler A, Erkeland SJ, Bodner C, Valkhof M, Renner W, Leitner C, et al. A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood 2005;105:3731-6. 70. Chakraborty A, White SM, Lerner SP. Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancer. Urology 2004;63:177-83. 71. Chakraborty A, Guha S. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology 2007;69:1210-5. 72. Hasselblatt M, Jeibmann A, Riesmeier B, Maintz D, Schabitz WR. Granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor expression in human ischemic stroke. Acta Neuropathol 2007;113:45-51. 73. Kastury K, Taylor WE, Shen R, Arver S, Gutierrez M, Fisher CE, et al. Complementary deoxyribonucleic acid cloning and characterization of a putative human axonemal dynein light chain gene. J Clin Endocrinol Metab 1997;82:3047-53. 74. Primdahl H, von der Maase H, Christensen M, Wolf H, Orntoft TF. Allelic deletions of Rb and L-myc in urine sediments from patients with bladder tumors or carcinoma in situ. Oncol Rep 2002;9:551-5. 75. Kambara T, Sharp GB, Nagasaka T, Takeda M, Sasamoto H, Nakagawa H, et al. Allelic loss of a common microsatellite marker MYCL1: a useful prognostic factor of poor outcomes in colorectal cancer. Clin Cancer Res 2004;10:1758-63. 76. Suzuki H, Yamashiro K. L-myc restriction fragment length polymorphism and histological pattern of invasion in lung adenocarcinoma. Oncol Rep 2002;9:345-7. 77. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002;16:2530-43. 78. Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 2008;68:1504-12. 79. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008;68:98-105. 80. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, et al. Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene 2003;22:3007-14. 81. Liu H, Cheng EH, Hsieh JJ. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev 2007;21:2385-98. 82. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 2008;27:1562-71. 83. Tao H, Shinmura K, Suzuki M, Kono S, Mibu R, Tanaka M, et al. Association between genetic polymorphisms of the base excision repair gene MUTYH and increased colorectal cancer risk in a Japanese population. Cancer Sci 2008;99:355-60. 84. Kobayashi K, Shida A, Yamada H, Ishibashi Y, Nakayama R, Toriumi Y, et al. Frequent splicing aberration of the base excision repair gene hMYH in human gastric cancer. Anticancer Res 2008;28:215-21. 85. Barnetson RA, Devlin L, Miller J, Farrington SM, Slater S, Drake AC, et al. Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. Clin Genet 2007;72:551-5. 86. Wang J, Ni H, Chen L, Liu YX, Chen CB, Song WQ. Preparation and analysis of cSNP chip on hepatocellular carcinoma-related genes. Hepatobiliary Pancreat Dis Int 2005;4:398-402. 87. Fromme JC, Banerjee A, Huang SJ, Verdine GL. Structural basis for removal of adenine mispaired with 8-oxoguanine by MutY adenine DNA glycosylase. Nature 2004;427:652-6. 88. Hoshino I, Matsubara H, Hanari N, Mori M, Nishimori T, Yoneyama Y, et al. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 2005;11:7945-52. 89. Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs TS, Park EM, et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 2003;19:285-98. 90. Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R, et al. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem 2002;277:19396-401. 91. Petrash JMA, N. H.; Sadana, I.; Srivastava, S. K. Biochemical and genetic interrelationship between aldose reductase, aldose reductase M and aldehyde reductase in human tissues.(Abstract) Am. J. Hum. Genet. 1981; 33. 92. Wang SS, Davis S, Cerhan JR, Hartge P, Severson RK, Cozen W, et al. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis 2006;27:1828-34. 93. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A 1997;94:2238-42. 94. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 2001;358:249-55. 95. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125:677-87. 96. Imaoka S, Yoneda Y, Sugimoto T, Hiroi T, Yamamoto K, Nakatani T, et al. CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem Biophys Res Commun 2000;277:776-80. 97. Hiratsuka M, Nozawa H, Konno Y, Saito T, Konno S, Mizugaki M. Human CYP4B1 gene in the japanese population analyzed by denaturing HPLC. Drug Metab Pharmacokinet 2004;19:114-9. 98. Powell PK, Wolf I, Lasker JM. Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Arch Biochem Biophys 1996;335:219-26. 99. Yeh CS, Wang JY, Cheng TL, Juan CH, Wu CH, Lin SR. Fatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by Microarray-Bioinformatics analysis. Cancer Lett 2006;233:297-308. 100. Cho BH, Park BL, Kim LH, Chung HS, Shin HD. Highly polymorphic human CYP4A11 gene. J Hum Genet 2005;50:259-63. 101. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-52. 102. Luedde T, Tacke F, Manns MP, Trautwein C. p18(INK4c) expression in hepatocellular carcinoma. Hepatology 2005;41:405; author reply 406. 103. Arcellana-Panlilio MY, Egeler RM, Ujack E, Magliocco A, Stuart GC, Robbins SM, et al. Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors. Genes Chromosomes Cancer 2002;35:176-81. 104. Sanchez-Aguilera A, Delgado J, Camacho FI, Sanchez-Beato M, Sanchez L, Montalban C, et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 2004;103:2351-7. 105. van Veelen W, van Gasteren CJ, Acton DS, Franklin DS, Berger R, Lips CJ, et al. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. Cancer Res 2008;68:1329-37. 106. Huang H, Gallegos AM, Zhou M, Ball JM, Schroeder F. Role of the sterol carrier protein-2 N-terminal membrane binding domain in sterol transfer. Biochemistry 2002;41:12149-62. 107. Yamamoto R, Kallen CB, Babalola GO, Rennert H, Billheimer JT, Strauss JF, 3rd. Cloning and expression of a cDNA encoding human sterol carrier protein 2. Proc Natl Acad Sci U S A 1991;88:463-7. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9821 | - |
dc.description.abstract | Background: In hepatocellular carcinomas (HCCs), frequent allelic loss on chromosome 1p has been reported. Using linkage analysis on multiplex families, a HCC-susceptibility locus has been mapped to a broad region of chromosome 1p32.2-36.1.
Materials and Methods: Here we have used a positional candidate gene strategy, based on association mapping with single nucleotide polymorphisms (SNPs) on 19 candidate genes within the linked region among 240 families with HCC, followed by a case-control analysis involving an independent set of 855 cases and 875 controls. Significance of the association was assessed by the false-discovery rate q value, which accounts for multiple testing. Results: In the family sample, we observed a significant association between HCC and five single-nucleotide polymorphisms (SNPs) in a haplotype block by using the pedigree disequilibrium test. SNP 13, located in the 3’ untranslated region (UTR) of the retinoblastoma binding protein 4 (RBBP4) gene, showed the strongest evidence (nominal P=0.0047; empirical P=0.0025; q=0.0188). Further case-control analysis confirmed the genetic association between SNP13 and HCC, and identified additional two SNPs in the same haplotype block. The C allele (minor allele) of SNP13 conferred an increased risk for HCC (odds ratio [95% confidence interval]: 1.36 [1.11-1.65] for heterozygotes; 1.29 [0.90-1.84] for homozygotes ). SNP13 and two neighboring SNPs fell on a common haplotype (‘C-A-C’ at SNP13-SNP14-SNP15), which was also associated with an increase risk of HCC. Conclusion: SNP13 was consistently associated with HCC in both family and case-control sample. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:43:24Z (GMT). No. of bitstreams: 1 ntu-97-R95842015-1.pdf: 453584 bytes, checksum: 004ad0dfea4b506112a0ecd1e284f5ec (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | Introduction ………………………………………………………1
Materials and Methods……………………………………………4 Results………………………………………………………………9 Discussion…………………………………………………………13 References…………………………………………………………16 Table 1 ……………………………………………………………28 Table 2 ……………………………………………………………30 Table 3 ……………………………………………………………31 Table 4 ……………………………………………………………32 Table 5 ……………………………………………………………33 Table 6 ……………………………………………………………34 Table 7 ……………………………………………………………35 Table 8 ……………………………………………………………36 Table 9 ……………………………………………………………37 Figure 1……………………………………………………………38 Figure 2……………………………………………………………39 Figure 3……………………………………………………………40 | |
dc.language.iso | en | |
dc.title | 染色體1p32.2-36.1區域肝癌易感受基因連鎖高峰之定位:候選基因策略 | zh_TW |
dc.title | Identification of Hepatocellular Carcinoma Susceptibility Gene by Peakwide Mapping on Chromosome 1p32.2-36.1:
Application of Positional Candidate Gene Approach | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 熊昭,范盛娟,簡國龍,高嘉宏 | |
dc.subject.keyword | 候選基因策略,家族研究,病例對照,關連性分析,肝癌易感受基因, | zh_TW |
dc.subject.keyword | Positional candidate gene approach,family study,case-control study,association study,HCC susceptibility gene, | en |
dc.relation.page | 40 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2008-07-21 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf | 442.95 kB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。